Incorporating a Patient Dichotomous Characteristic in Cancer Phase I Clinical Trials Using Escalation with Overdose Control

Table 2

EWOC with no Covariate. Design operating characteristic with respect to safety of the trial.

(𝛾0, 𝛾1)	0.2, 0.4	0.2, 0.6	0.2, 0.8	0.4, 0.6	0.4, 0.8	0.6, 0.8
Proportion of DLTs	0.3156	0.3172	0.3143	0.2824	0.2702	0.2370
Proportion of DLTs in group A	0.3170	0.3180	0.3105	0.2856	0.2737	0.2389
Proportion of DLTs in group B	0.3142	0.3164	0.3180	0.2791	0.2668	0.2350
Proportion overdosed in group A	0.6495	0.7415	0.775	0.4091	0.5298	0.1761
Proportion overdosed in group B	0.0184	0.0006	0.0000	0.0109	0.0000	0.0003